Cargando…
Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy
The treatment of metastatic urothelial carcinoma has dramatically changed over the past decade with the approval of several therapies from multiple drug classes including immune checkpoint inhibitors, targeted therapies, and antibody drug conjugates. Although next generation sequencing of urothelial...
Autores principales: | Benjamin, David J., Hsu, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477976/ https://www.ncbi.nlm.nih.gov/pubmed/37675102 http://dx.doi.org/10.3389/fimmu.2023.1258388 |
Ejemplares similares
-
FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer
por: Kacew, Alec, et al.
Publicado: (2020) -
Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
por: Benjamin, David J, et al.
Publicado: (2022) -
Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy
por: Tang, Qi, et al.
Publicado: (2023) -
Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma
por: Lyou, Yung, et al.
Publicado: (2022) -
Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations
por: Lima, Nadia Carvalho, et al.
Publicado: (2020)